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Robert J. Ginsberg, MD 
T he thoracic surgical group at the National Cancer Center Hospital in Tokyo has had a long history 
of reporting results of superbly staged resected lung 
cancers. Their previous detailed analyses have 
helped to define subset survival after complete 
resection in the management of non-small-cell lung 
cancer. 
This current analysis focuses on the small periph- 
eral lesion less than 3 cm in diameter and identifies 
the fact that almost one quarter of the patients had 
lymph node involvement either within the lung or 
within the mediastinal lymph nodes. An interesting 
feature is that in those patients with T1 NO disease 
clinically staged by chest roentgenography and com- 
puted tomography, almost 10% (27/305) were found 
to have intrapulmonary spread by virtue of lym- 
phatic dissemination r satellite lesions and almost 
15% (44/305) had metastatic mediastinal lymph 
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node involvement. Even in cases of tumors that 
measured less than 2 cm in diameter, a full 20% of 
patients had unsuspected lymph node disease. An- 
other interesting feature of this analysis is that of all 
patients with N2 disease, 25% had no lymphatic 
involvement within the pulmonary tissue removed 
but did have "skipping" metastases in the mediasti- 
num. This has been identified previously in reports 
both from North America and Japan. 
As has been the practice at Memorial Sloan 
Kettering Cancer Center, the National Cancer Cen- 
ter group of surgeons has always advocated com- 
plete ipsilateral mediastinal lymphadenectomy in 
association with pulmonary resection for lung can- 
cer. The astounding 92% 5-year survival in patients 
with T1 NO disease probably reflects the results in a 
very pure group of patients, with T1 NO fastidiously 
staged. In a similar group of patients treated by 
lobectomy by the Lung Cancer Study Group but 
staged only by lymph node sampling, the 5-year 
survival approached 70%, but both reports had a 
similar cancer recurrence rate of approximately 
20%. 1 
This report's recommendation that mediastinal 
lymphadenectomy be considered part of the appro- 
priate surgical resection for lung cancer is tantaliz- 
ing. Mediastinal lymphadenectomy hasnever been 
demonstrated to improve survival, but it has been 
shown that, although it increases operating time by 
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20 to 30 minutes, it does provide for the best 
possible surgical staging and allows for a complete 
surgical resection in patients with unsuspected me- 
diastinal disease Without added morbidity. The 
44.5% 5-year suivival for this select group of pa- 
tients with T1 N2 disease matches the survival seen 
in other reports of single station N2 disease that is 
completely resected. Every patient undergoing re- 
section in the treatment of lung cancer deserves 
complete intraoperative staging: mediastinal lymph 
node dissection accomplishes thatgoal. 
On the basis of this detailed retrospective analy- 
sis, the authors of this paper also infer that resec- 
tions less than lobectomy might not be adequate 
even in patients with clinically staged T1 NO disease 
and even in those patients with peripheral lesions 
less than 2 cm in diameter because of the significant 
prevalence of intrapulmonary and mediastinal met- 
astatic disease. The only exception to the rule might 
be very small peripheral squamous cell tumors. A 
similar conclusion has been reached by the Lung 
Cancer Study Group on the basis of an almost 
threefold prevalence of locoregional recurrence in a 
group of patients with T1 NO tumors treated by 
limited resection when compared with results in a 
similar group randomized to lobectomy. 1 
Whether surgical resection is done by a large 
posterolateral thoracotomy, a video-assisted ap- 
proach, or something in between, the basic princi- 
ples of cancer surgery must always be adhered to; 
that is, complete resection and adequate surgical 
staging. 
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